Article
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.
The New England journal of medicine - 16 Jan 2014
Kowdley Kris V, Lawitz Eric, Poordad Fred, Cohen Daniel E, Nelson David R, Zeuzem Stefan, Everson Gregory T, Kwo Paul, Foster Graham R, Sulkowski Mark S, Xie Wangang, Pilot-Matias Tami, Liossis George, Larsen Lois, Khatri Amit, Podsadecki Thomas, Bernstein Barry
Abstract excerpt
BACKGROUND: An interferon-free combination of the protease inhibitor ABT-450 with ritonavir (ABT-450/r), the nonnucleoside polymerase inhibitor ABT-333, and ribavirin showed efficacy against the hepatitis C virus (HCV) in a pilot study involving patients with HCV genotype 1 infection. The addition of another potent agent, the NS5A inhibitor ABT-267, may improve efficacy, especially in difficult-to-treat patients....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.